Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
This project was designed To explore the pathological complete response (pCR) of lorlatinib as neoadjuvant treatment. Twenty-five patients will be involved in this study.
These patients will receive lorlatinib neoadjuvant therapy for 6-8 weeks (determined by clinicians' decision based on clinical practice) and then underwent surgery.
Previous small-sample clinical studies on ALK inhibitors as neoadjuvant therapy in resectable NSCLC have shown promising outcomes including MPR and pCR, supporting the potential of ALK TKIs in this setting.
Phase:
PHASE2
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
Air Force Military Medical University, China Hunan Cancer Hospital Liaoning Cancer Hospital & Institute Second Affiliated Hospital, School of Medicine, Zhejiang University